Lazari Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Lazari Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8K	Hold	10,500	–	–	﹤0.01%	186
2026 Q1	$16.6K	Hold	10,500	–	–	0.01%	173
2025 Q4	$17.5K	Sell	10,500 -317	-3%	-$549	0.01%	163
2025 Q3	$18.3K	Hold	10,817	–	–	0.01%	165
2025 Q2	$9.81K	Hold	10,817	–	–	﹤0.01%	155
2025 Q1	$4.88K	Sell	10,817 -147	-1%	-$86	﹤0.01%	153
2024 Q4	$5.51K	Buy	+10,964	New	+$8.05K	﹤0.01%	152

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

RCWM

Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

TCOT

Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

BWCS

Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Lazari Capital Management's LCTX Position: Q2 2026 in Review

Lazari Capital Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 10,500 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #186.

Lazari Capital Management first reported a position in LCTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $18.3K in Q3 2025. 32 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Lazari Capital Management held 10,500 shares of Lineage Cell Therapeutics worth $13.8K as of Q2 2026.
Lazari Capital Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Lazari Capital Management's portfolio in Q2 2026, its #186 holding.
Lazari Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 7 quarters since.
Lazari Capital Management's Lineage Cell Therapeutics position peaked at $18.3K in Q3 2025.
32 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Lazari Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.